Risk Minimisation Materials

Kadcyla (trastuzumab emtansine) EU Healthcare Professional Information - prevention of medication errors

This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan. Please register or log in to view the materials.

For Healthcare Professionals

Kanuma: A Guide For Healthcare Professionals

Please read this guide carefully and use it when prescribing KANUMA® as it contains essential safety and efficacy information. The guide was created as part of the KANUMA® Risk Management Plan and includes risk-minimising measures for the safe and effective use of this medicinal product. The guide is a mandatory part of the approval process for KANUMA®, to help ensure that healthcare professionals take into account the special safety requirements of prescribing this medicinal product.

DHCP Keppra Oral solution

Dear Healthcare Professional Communication related to risk of medication errors associated with overdose for Keppra Oral solution.

For Healthcare Professionals

Checklist for the prescriber

Checklist for the prescriber: Minimising the risk of photosensitivity with topical ketoprofen

For Healthcare Professionals

Information sheet for patients

Information sheet for patients: Minimising the risk of skin reactions with topical ketoprofen

Kevzara (sarilumab)- Patient Alert card-Risk Minimisation Information for Patients

This patient alert card contains important safety information that you need to be aware of before, during, and after treatment with KEVZARA For hard copies please contact our medical information department at 0845 372 7101 or email uk-medicalinformation@sanofi.com .

Kevzara -Healthcare Professional Letter- Risk Minimisation Information for Healthcare Professionals’

For hard copies please contact our medical information department at 08453727101 or email ukmedinfo@sanofi.com

For Healthcare Professionals

Keytruda (Pembrolizumab): Patient Alert Card

The provision of this card to patients is required by the terms of the Marketing Authorisation. Please ensure that you carry this card with you at all times and that you have read and understood this information as it contains important safety information that you need to be aware of before, during and after treatment with pembrolizumab

Keytruda (pembrolizumab): Important safety information to minimise the risk of immune-related adverse reactions: Heathcare Professional Frequently Asked Questions

As part of the terms of the Marketing Authorisation for Keytruda, MSD are required to ensure that all Healthcare Professionals who are likely to treat patients with pembrolizumab are provided with risk minimisation materials This document contains key information to help minimize the risk of immune-mediated side-effects such as immune-related pneumonitis, colitis, hepatitis, nephritis, endocrinopathies (including hypophysitis, type 1 diabetes mellitus,(including diabetic ketoacidosis, hypothyroidism, hyperthyroidism, and thyroiditis)) and other immune-related adverse reactions, providing guidance on how to monitor and manage them. It also draws attention to the availability of the Patient Information Brochure and Patient Alert Card. If you require further information about pembrolizumab and hard copies of the material please contact medicalinformationuk@merck.com. If you have any questions or require additional information, please call MSD Medical Information services on 01992 467272.

For Healthcare Professionals

Keytruda (pembrolizumab): Information for Patients Brochure: Important safety information to minimise the risk of immune-related adverse reactions

As part of the terms of the Marketing Authorisation for Keytruda, MSD are required to provide patients with information to help minimise the risk of immune-related adverse reactions that may occur with treatment with pembrolizumab. Please ensure that you have read and understood this information as it contains important safety information that you need to be aware of before, during and after treatment with pembrolizumab.

Keytruda- explanatory note to RMM

Updated RMM were distributed to an agreed list of HCPs on 26 April 2018. This updates the product information for Keytruda with the risks of encephalitis, sarcoidosis and graft versus host disease (GVHD) after pembrolizumab administration in patients with a history of allogeneic hematopoietic stem cell transplant (HSCT)

Keytruda RMM- Dear HCP cover letter

Cover Letter accompanying updated RMM issued in April 2018 Reflects the update to the product information to include the risks of encephalitis, sarcoidosis and graft versus host disease (GVHD) after pembrolizumab administration in patients with a history of allogeneic hematopoietic stem cell transplant (HSCT)

For Healthcare Professionals

Kineret Patient Booklet

The material above is available for Kineret when used in the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) and Still’s disease, including Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still’s Disease (AOSD).

Kineret Patient Card

Patient reminder card to be used by patients with Still's disease.

Using Kineret. A Guide for Healthcare Professionals

The material above is available for Kineret when used in the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), and Still’s disease, including Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still’s Disease (AOSD).

For Healthcare Professionals

Abacavir Hypersensitivity Slide Deck for Healthcare Professionals

Abacavir Hypersensitivity Slide Deck for Healthcare Professionals

For Healthcare Professionals

Abacavir Hypersensitivity Website for Healthcare Professionals

Abacavir Hypersensitivity Website for Healthcare Professionals

For Healthcare Professionals

Bayer Intrauterine System Educational Pack

Differentiation of Kyleena, Jaydess and Mirena

For Healthcare Professionals